Canagliflozin - Latest Advances

Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trial.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: September 04, 2026

SGLT2i Canagliflozin Exerts Neuroprotection in Diabetic Retinopathy by Inhibiting Microglial Proinflammatory Cytokine Release by Downregulating the TLR4/NF-κB/NLRP3 Pathway.

Journal: Current eye research

Published: August 11, 2026

A closer insight into the molecular effect of canagliflozin on gentamicin-induced nephrotoxicity in rats: Attention to SIRT1/Nrf2/HO-1, p38 MAPK/NF-κB signaling pathways, and expression of miR-21 and miR-155.

Journal: Immunopharmacology and immunotoxicology

Published: August 03, 2026

Study on mechanism of ultrafiltration membrane extract of Angelicae Sinensis Radix and Hedysari Radix regulates mitochondrial function to ameliorate diabetic kidney disease

Journal: Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica

Published: August 02, 2026

Dose and sex-specificity in Canagliflozin-mediated neuroprotection in aging mice.

Journal: bioRxiv : the preprint server for biology

Published: July 17, 2026

Multi-Tissue Metabolomic Signatures of Five Longevity Interventions Converge on Ergothioneine and Lipid Remodeling in Male UM-HET3 Mice.

Journal: bioRxiv : the preprint server for biology

Published: July 10, 2026

Are SGLT2 inhibitors really associated with increased urinary tract infection risk? A trial-level meta-analysis across type 2 diabetes, heart failure, and chronic kidney disease.

Journal: Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences

Published: June 30, 2026

SGLT2 Inhibitors Promote Diabetic Wound Healing Via AMPK/AKT/mTORC1-Regulated Endothelial Angiogenesis.

Journal: Arteriosclerosis, thrombosis, and vascular biology

Published: June 25, 2026

A Microsimulation Model for Chronic Kidney Disease Progression in Type 2 Diabetes Patients in the United States: Michigan Model for Diabetes-Chronic Kidney Disease Model.

Journal: Medical decision making : an international journal of the Society for Medical Decision Making

Published: June 19, 2026

Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Left Ventricular Global Longitudinal Strain in Adults with Type 2 Diabetes Mellitus: A Systematic Review.

Journal: Journal of clinical medicine

Published: June 10, 2026

Effects of canagliflozin on end-stage kidney disease and cardiovascular mortality in adults aged 50 years or older: an individual participant data meta-analysis of the CANVAS and CREDENCE trials.

Journal: Diabetes research and clinical practice

Published: June 04, 2026

Short-term comparative effects of semaglutide, either alone or in conjunction with canagliflozin, on early diabetic kidney disease.

Journal: Pakistan journal of pharmaceutical sciences

Published: May 22, 2026